Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Abstract

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

1 - 30 . (canceled) 
     
     
         31 . A method comprising:
 obtaining a circulating blood sample from an individual; and   detecting protein levels for each member of a list of proteins in the sample, the list comprising CATD, SEPR, CEA, MIF, and PSGL.   
     
     
         32 . The method of  claim 31 , further comprising
 diagnosing the individual as having a colorectal cancer risk status when the protein levels from the individual do not differ significantly from a reference panel information set corresponding to a known colorectal cancer risk status; and   performing a polypectomy on the individual.   
     
     
         33 . The method of  claim 32 , further comprising providing instructions indicating a recommendation to perform chemotherapy on the individual. 
     
     
         34 . The method of  claim 32 , further comprising providing instructions indicating a recommendation to perform radiotherapy on the individual. 
     
     
         35 . The method of  claim 32 , wherein diagnosing comprises a sensitivity of at least 60%. 
     
     
         36 . The method of  claim 32 , further comprising obtaining age information for the individual. 
     
     
         37 . The method of  claim 32 , further comprising obtaining gender information for the individual, and wherein diagnosing the individual as having the colorectal cancer risk status when the protein levels and the gender information from the individual do not differ significantly from a reference panel information set corresponding to a known colorectal cancer risk status. 
     
     
         38 . The method of  claim 31 , wherein the list of proteins further comprises AACT. 
     
     
         39 . The method of  claim 31 , further comprising transmitting a report of results of the detecting to a health practitioner. 
     
     
         40 . The method of  claim 39 , wherein the report recommends that a colonoscopy be performed. 
     
     
         41 . The method of  claim 31 , wherein the detecting protein levels comprises contacting a fraction of the circulating blood sample to a set of antibodies comprising antibodies specific to CATD, SEPR, CEA, MIF, and PSGL. 
     
     
         42 . The method of  claim 31 , wherein the list of proteins comprises no more than 8 proteins. 
     
     
         43 . The method of  claim 31 , wherein the list of proteins comprises no more than 15 proteins. 
     
     
         44 . A method of monitoring efficacy of a colorectal cancer treatment regimen in an individual, comprising the steps of:
 obtaining a first sample comprising circulating blood from the individual at a first time point;   administering the colorectal cancer treatment regimen to the individual;   obtaining a second sample comprising circulating blood from the individual at a second time point after the colorectal cancer treatment regimen; and   determining protein levels for each member of a list of proteins comprising CATD, SEPR, CEA, MIF, and PSGL in the first sample and determining protein levels for each member of the list of proteins comprising CATD, SEPR, CEA, MIF, and PSGL in the second sample.   
     
     
         45 . The method of  claim 44 , wherein obtaining the first sample comprises receiving plasma drawn from a vein or artery of the individual. 
     
     
         46 . The method of  claim 44 , wherein the treatment regimen comprises a polypectomy. 
     
     
         47 . The method of  claim 44 , wherein the treatment regimen comprises chemotherapy. 
     
     
         48 . The method of  claim 44 , wherein the treatment regimen comprises radiotherapy. 
     
     
         49 . The method of  claim 44 , wherein the list of proteins further comprises AACT and CO3. 
     
     
         50 . The method of  claim 44 , further comprising changing the treatment regimen when protein levels for the first sample are the same as the protein levels for the second sample. 
     
     
         51 . The method of  claim 44 , further comprising repeating the treatment regimen when protein levels for the first sample are the same as the protein levels for the second sample. 
     
     
         52 . The method of  claim 44 , further comprising discontinuing the treatment regimen when protein levels of the second sample return to levels corresponding to a healthy individual. 
     
     
         53 . The method of  claim 44 , wherein the list of proteins comprises no more than 8 proteins. 
     
     
         54 . The method of  claim 44 , wherein the list of proteins comprises no more than 15 proteins. 
     
     
         55 . The method of  claim 44 , further comprising obtaining age information for the individual; and providing instructions to indicate changing or repeating the treatment regimen, wherein the instructions is based on the age information, and the protein levels for the first sample and the protein levels for the second sample. 
     
     
         56 . The method of  claim 44 , further comprising obtaining gender information for the individual; and providing instructions to indicate changing or repeating the treatment regimen, wherein the instructions is based on the gender information, and the protein levels for the first sample and the protein levels for the second sample.